WO2002062790A1 - Preparation of n-methylparoxetine and related intermediate compounds - Google Patents
Preparation of n-methylparoxetine and related intermediate compounds Download PDFInfo
- Publication number
- WO2002062790A1 WO2002062790A1 PCT/US2002/003223 US0203223W WO02062790A1 WO 2002062790 A1 WO2002062790 A1 WO 2002062790A1 US 0203223 W US0203223 W US 0203223W WO 02062790 A1 WO02062790 A1 WO 02062790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- yield
- sesamol
- organic solvent
- methylparoxetine
- Prior art date
Links
- 0 **(CC1)C(CO*)CC1N=C Chemical compound **(CC1)C(CO*)CC1N=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Definitions
- the field of the invention is synthesis of paroxetine and like compounds, more specifically the preparation of an intermediate in the synthesis of paroxetine.
- Paroxetine is an orally administered antidepressant for the treatment of depression, social anxiety disorders, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder and posttraumatic stress disorder.
- Paroxetine is marketed as Paxil ® by Glaxo SmithKline.
- Paxil ® is prescribed as oral dosage tablets containing lOmg, 20mg, 30mg and 40mg of the base equivalent of paroxetine hydrochloride.
- Paxil ® tablets include dibasic calcium phosphate dihydrate, hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycols, polysorbate 80, sodium starch glycolate, titanium dioxide and one or more of the following: D&C Red No. 30, D&C Yellow No. 10, FD&C Blue No. 2, FD&C Yellow No. 6.
- Paxil ® is also available as an oral suspension with a dosage of 10 mg of the base equivalent of paroxetine hydrochloride in a 5 mL suspension containing polacrilin potassium, microcrystalline cellulose, propylene glycol, glycerin, sorbitol, methyl paraben, propyl paraben, sodium citrate dihydrate, citric acid anhydrate, sodium saccharin, flavorings, FD&C Yellow No. 6 and simethicone emulsion, USP.
- Paroxetine may be produced by synthesizing an intermediate, N-methylparoxetine, wherein the methyl group is attached to the amine of the piperidine group.
- the amine is a secondary amine, while in the intermediate, the amine is a tertiary amine.
- N-methyl paroxetine has the following structure (II):
- the '196 patent discloses obtaining N-methylparoxetine by reacting 4-(4-fluorophenyl)-3- chloromethyl-N-methyl-piperidine, also named CIPMA of structure (III):
- N-methylparoxetine U.S. Pat. No. 4,007,196 reacts CIPMA with sesamol in a solution of sodium in methanol, giving N-methylparoxetine with a yield of about 25%.
- the '777 patent first prepares an -methyl intermediate by reacting in examples 5 and 8 the sulfonate esters of the enantiomers of cis-4-(4- fluorophenyl)-3-hydroxymethyl-l-methylpiperidine with p-methoxyphenol.
- the '777 patent does not give a yield for example 5.
- 38.5 grams of the ester were used to obtain 1.8 grams of the product as a free base, giving a yield of about 5%.
- N-methylparoxetine results in lower yields of paroxetine.
- the low yield increases the cost of the process and requires additional purification.
- the present invention provides a process for preparing compound (VII) comprising reacting compound (V) with compound (VI) in an organic solvent:
- X is selected from the group consisting of halogen and -OSO2R 3 ;
- Ar is phenyl optionally substituted by halogen, alkoxy or other inert group;
- R 1 is selected from the group consisting of hydrogen, alkyl, aralkyl, alkaryl, alkyloxycarbonyl, aryloxycarbonyl and arylalkoxycarbonyl;
- R 2 is selected from the group consisting of aryl and heteroaryl, wherein any one or more of said aryl and heteroaryl are optionally substituted by the group consisting of alkyl, halogen, alkoxy, nitro, acylamino, methylenedioxy, alkyl sulfonyl, aryl sulfonyl, alkaryl sulfonyl and aralkyl sulfonyl; and
- R 3 is selected from the group consisting of alkyl, aryl, aralkyl and alkaryl.
- the present invention provides a process for preparing N- methylparoxetine comprising reacting CIPMA with sesamol-tetrabutylammonium salt in an organic solvent.
- the present invention provides for sesamol-tetrabutylammonium salt.
- yield refers to the moles of the intermediate obtained
- VII preferably N-methylparoxetine
- V preferably CIPMA
- NBu 4 refers to tetrabutylammonium ion.
- CIPMA and sesamol were reacted in the presence of polar solvents such as dimethylformamide, acetone or methylethylketone and strong bases such as sodium hydroxide, sodium methoxide and potassium tert-butoxide, and non-polar solvents such as toluene, dichloromethane or methyl-iso-butyl ketone in liquid-liquid PTC (phase transfer catalysis) reactions.
- CIPMA was also reacted by the Applicant with sesamol in liquid-solid PTC reactions in the presence of solvents such as toluene or acetonirile.
- the PTC reactions were performed in the presence of bases such as sodium hydroxide, potassium hydroxide, potassium carbonate or barium hydroxide. Tetrabutylammonium bromide arid tricaprylmethylammonium chloride, tributylbenzylammonium bromide, PEG 400 were used as PTC catalysts.
- bases such as sodium hydroxide, potassium hydroxide, potassium carbonate or barium hydroxide.
- Tetrabutylammonium bromide arid tricaprylmethylammonium chloride, tributylbenzylammonium bromide, PEG 400 were used as PTC catalysts.
- the present invention provides a process for producing N-methylparoxetine and similar intermediates with reactions that result in a higher yield than that obtained in the prior art. Specifically, the process of the present invention obtains a yield of about 86%, which is much higher than the 25% yield of the prior art.
- the present invention is directed to the use of sesamol-tetrabutylammonium salt to increase the yield of N-methylparoxetine obtained.
- the salt may be prepared by dissolving sesamol and tetrabutylammonium hydroxide in an alcohol or a mixture of alcohols.
- the alcohol used is a mixture of isopropanol and methanol.
- the solvents are then evaporated, preferably under reduced pressure to obtain a residue, the salt.
- a salt of tetrabutylammonim such as the bromide salt, may be added in conjunction with a base, such as sodium hydroxide.
- the salt is added to a mixture of CIPMA and a solvent such as acetonitrile, toluene or isopropanol.
- a solvent such as acetonitrile, toluene or isopropanol.
- the reaction mixture comprising CIPMA, sesamol-tetrabutylammonium salt and a solvent is preferably heated for a few hours, most preferably for about 4 hours at reflux. The reaction mixture is then cooled and the solvent is removed to obtain a residue.
- the solvent is removed by evaporation under reduced pressure.
- the residue is then dissolved in an organic solvent, such as toluene and is washed with a polar solvent such as water and a base such as sodium hydroxide.
- a polar solvent such as water and a base such as sodium hydroxide.
- the reaction mixture is then dried by using a drying agent such as sodium sulfate and the solvent is evaporated to obtain N-methylparoxetine.
- the present invention obtains a yield of about
- the present invention provides a process for preparing compound (VII) comprising reacting compound (V) with compound (VI) in an organic solvent:
- X is selected from the group consisting of halogen and -OSO2 R 3 ;
- Ar is phenyl optionally substituted by halogen, alkoxy or other inert group
- R 1 is selected from the group consisting of hydrogen, alkyl, aralkyl, alkaryl, alkyloxycarbonyl, aryloxycarbonyl and arylalkoxycarbonyl;
- R 2 is selected from the group consisting of aryl and heteroaryl, wherein any one or more of said aryl and heteroaryl are optionally substituted by the group consisting of alkyl, halogen, alkoxy, nitro, acylamino, methylenedioxy, alkyl sulfonyl, aryl sulfonyl, alkaryl sulfonyl and aralkyl sulfonyl; and R 3 is selected from the group consisting of alkyl, aryl, aralkyl and alkaryl.
- CIPMA can be obtained by using a metal hydride, such as lithium aluminum hydride, to reduce an ester to an alcohol, as taught in U.S. Pat. No. 4,007,196.
- the formed alcohol is a precursor of CIPMA.
- the alcohol is then converted to an alkyl halide because a halogen is a better leaving group than a hydroxide group.
- the present invention uses a leaving group which is preferably either a halogen or a sulfonyl group.
- a hydroxide group is not a good leaving group, which makes its conversion to a halogen or a sulfonyl group necessary.
- a sulfonyl compound is often used to convert an alcohol to a sulfonate ester.
- the sulfonyl compounds which may be used to convert the alcohol into a sulfonate ester are for example a typical sulfonyl chloride such as trifluoromethanesulfonyl chloride and p-toluenesulfonyl chloride.
- Pyridine is generally used as a solvent in such reactions in order to neutralize the formed hydrochloric acid, a byproduct of the reaction.
- the present invention prefers the use of halogens as a leaving group.
- the most preferred halogen is chlorine, with others being iodine and bromine.
- the leaving group in CIPMA is a chlorine.
- the conversion of an alcohol to an alkyl halide is well known in the art.
- Phosphorous tribromide (PBr 3 ), phosphorous trichloride (PC1 3 ) and thionyl chloride (SOCl 2 ) may be used to convert the alcohol into an alkyl halide.
- Pyridine may be used as a solvent to neutralize any formed hydrochloric acid.
- the present invention reacts compound V with compound VI.
- Compound V comprises of a piperidine and an aryl group.
- the aryl group of compound (V) may be substituted with a halogen, an alkoxy group or other inert groups.
- inert group refers to homologs of benzene, where by replacing a hydrogen on the aryl group with a CH 3 or higher alkyl groups, a series of homologs may be made, such as toluene or ethylbenzene.
- the aryl group of compound (V) is substituted with a fluorine.
- the most preferable embodiment of the present invention has the fluorine in a para position because the fluorine is in the para position in paroxetine. (See compound (I)).
- Groups that may be connected to the amine of the piperidine in compound (V) may include hydrogen, alkyl, aralkyl, alkaryl, alkyloxycarbonyl, aryloxycarbonyl and arylalkoxycarbonyl. These groups, other than the hydrogen, act as protecting groups, by preventing reactions involving the amine group. Alkyls, particularly methyl groups are preferred. One skilled in the art may appreciate that other protecting groups known in the art may be used, and that the particular group used may not necessarily affect the result.
- the present invention optionally and preferably removes the protecting group.
- the methyl group of N-methylparoxetine may be removed by transformation to carbamate followed by alkaline hydrolysis.
- N-methylparoxetine may be reacted with phenyl chloroformate.
- the formed carbamate is then treated with a base such as KOH.
- a base such as KOH.
- Compound (VI) of the present invention may comprise of an aryl or a heteroaryl, which is optionally substituted by the group consisting of alkyl, halogen, alkoxy, nitro, acylamino, methylenedioxy, alkyl sulfonyl, aryl sulfonyl and alkaryl sulfonyl.
- Sesamol has an aryl group which is substituted by methylenedioxy.
- sesamol is the most preferred embodiment of the present invention because it leads to formation of N-methylparoxetine.
- the scope of the claims however are broader than sesamol and cover compounds with aryl and heteroaryl groups which are optionally substituted with groups other than methylenedioxy.
- the most preferred embodiment of the present invention provides a process for preparing N-methylparoxetine comprising reacting CIPMA with sesamol- tetrabutylammonium salt (compound VIII) in an organic solvent.
- the organic solvent is an aprotic polar solvent.
- the aprotic polar solvent is acetonitrile.
- the present invention is not limited to the use of an aprotic polar solvent to achieve high yields. The present invention also obtains high yields by use of protic and non-polar solvents.
- the present invention uses aromatic solvents.
- the aromatic solvent used is toluene.
- Other solvents with relatively the same polarity as toluene are preferred.
- the yield of the present invention using toluene as a solvent was about 86%.
- the present invention also uses an alcohol to carry out the reaction.
- the alcohol is a to a C 6 alcohol.
- the alcohol used is isopropanol.
- solvents that may be used include esters of fatty acids, aliphatic hydrocarbons and ethers.
- stereoisomer obtained plays a critical role in the effectiveness of a drug.
- the most preferred stereoisomers are those arranged like paroxetine.
- Sesamol (4.32g, 31.2 mmol) was added to a solution of tetrabutylammonium hydroxide in isopropanol/methanol (0.1N, 342 mL), and the solvents were evaporated under vacuum to dryness.
- the residual tetrabutylammonium salt of sesamol was dissolved in acetonitrile (40 mL) and 4-(4-fluorophenyl)-3-chloromethyl-N-methyl-piperidine
- Sesamol (4.76g, 34.2mmol) was added to a solution of tetrabutylammonium hydroxide in isopropanol/methanol (0.1N, 342 mL), and the solvents were evaporated under vacuum to dryness.
- the residual tetrabutylammonium salt of sesamol was dissolved in acetonitrile (40 mL) and 4-(4-fluorophenyl)-3-chloromethyl-N-methyl-piperidine
- Sesamol (4.76g, 34.2mmol) was added to a solution of tetrabutylammonium hydroxide in isopropanol/methanol (0.1N, 342 mL), and the solvents were evaporated under vacuum to dryness.
- the residual tetrabutylammonium salt of sesamol was dissolved in toluene (40 mL) and 4-(4-fluorophenyl)-3-chloromethyl-N-methyl-piperidine (CIPMA) 7.5g (31.2mmol) was added.
- the reaction mixture was stirred with heating at reflux for 4 hrs. After cooling, the reaction mixture was washed with 5% aq. sodium hydroxide and then with water. After drying with sodium sulfate and evaporation of the solvent in vacuum N-methylparoxetine (9.1 grams) was obtained with yield 85%.
- Sesamol (4.76g, 34.2mmol) was added to a solution of tetrabutylammonium hydroxide in isopropanol /methanol (0.1N, 342 mL), and the solvents were evaporated under vacuum to dryness.
- the residual tetrabutylammonium salt of sesamol was dissolved in isopropyl alcohol (40 mL) and 4-(4-fluorophenyl)-3-chloromethyl-N-methyl-piperidine (CIPMA) 7.5g (31.2mmol) was added.
- the reaction mixture was stirred with heating at reflux for 4 hrs. After cooling, the reaction mixture was evaporated to dryness in vacuum and the residue was dissolved in toluene.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15724302A IL157243A0 (en) | 2001-02-05 | 2002-02-04 | Preparation of n-methylparoxetine and related intermediate compounds |
SK1099-2003A SK10992003A3 (en) | 2001-02-05 | 2002-02-04 | Preparation of N-methylparoxetine and related intermediate compounds |
KR10-2003-7010266A KR20040014452A (en) | 2001-02-05 | 2002-02-04 | Preparation of n-methylparoxetine and related intermediate compounds |
EP02702143A EP1366041A4 (en) | 2001-02-05 | 2002-02-04 | Preparation of n-methylparoxetine and related intermediate compounds |
CA002437392A CA2437392A1 (en) | 2001-02-05 | 2002-02-04 | Preparation of n-methylparoxetine and related intermediate compounds |
HU0303153A HUP0303153A2 (en) | 2001-02-05 | 2002-02-04 | Preparation of n-methylparoxetine and its intermediate compounds |
HR20030690A HRP20030690A2 (en) | 2001-02-05 | 2003-09-01 | Preparation of n-methylparoxetine and related intermediate compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26649801P | 2001-02-05 | 2001-02-05 | |
US60/266,498 | 2001-02-05 | ||
US27758701P | 2001-03-21 | 2001-03-21 | |
US60/277,587 | 2001-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002062790A1 true WO2002062790A1 (en) | 2002-08-15 |
Family
ID=26951885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/003223 WO2002062790A1 (en) | 2001-02-05 | 2002-02-04 | Preparation of n-methylparoxetine and related intermediate compounds |
Country Status (10)
Country | Link |
---|---|
US (1) | US6777554B2 (en) |
EP (1) | EP1366041A4 (en) |
KR (1) | KR20040014452A (en) |
CA (1) | CA2437392A1 (en) |
CZ (1) | CZ20032354A3 (en) |
HR (1) | HRP20030690A2 (en) |
HU (1) | HUP0303153A2 (en) |
IL (1) | IL157243A0 (en) |
SK (1) | SK10992003A3 (en) |
WO (1) | WO2002062790A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001270858A1 (en) * | 2000-07-17 | 2002-01-30 | Smithkline Beecham Plc | Novel processes for the preparation of 4-phenylpiperidine derivatives |
US20080029575A1 (en) * | 2006-08-02 | 2008-02-07 | Shelton Frederick E | Surgical cutting and fastening instrument with distally mounted pneumatically powered rotary drive member |
US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002006275A1 (en) * | 2000-07-17 | 2002-01-24 | Smithkline Beecham P.L.C. | Novel processes for the preparation of 4-phenylpiperidine derivatives |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
US4585777A (en) | 1984-02-07 | 1986-04-29 | A/S Ferrosan | (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT |
DE3680184D1 (en) | 1985-08-10 | 1991-08-14 | Beecham Group Plc | METHOD FOR PRODUCING ARYLPIPERIDINE CARBINOL. |
IE66332B1 (en) | 1986-11-03 | 1995-12-27 | Novo Nordisk As | Piperidine compounds and their preparation and use |
GB8714707D0 (en) | 1987-06-23 | 1987-07-29 | Beecham Group Plc | Chemical process |
EP0351283A1 (en) | 1988-07-12 | 1990-01-17 | Synthelabo | 2-[(4-Piperidinyl)methyl]-2,3-dihydro-1H-isoindole and 2,3,4,5-tetrahydro-1H-benzazepine derivatives, their preparation and therapeutical use |
FR2634207B1 (en) | 1988-07-12 | 1990-09-07 | Synthelabo | ((PIPERIDINYL-4) METHYL) BENZAZEPINES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2659323B1 (en) | 1990-03-07 | 1992-06-12 | Synthelabo | DERIVATIVES OF 4- (AMINOMETHYL) PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
US5258517A (en) | 1992-08-06 | 1993-11-02 | Sepracor, Inc. | Method of preparing optically pure precursors of paroxetine |
US6004990A (en) | 1994-06-03 | 1999-12-21 | Zebra Pharmaceuticals | Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor |
GB9526645D0 (en) | 1995-12-28 | 1996-02-28 | Chiroscience Ltd | Stereoselective synthesis |
JP3882224B2 (en) | 1996-05-31 | 2007-02-14 | 旭硝子株式会社 | Method for producing paroxetine |
ES2331937T3 (en) | 1996-06-13 | 2010-01-20 | Sumitomo Chemical Company, Limited | DERIVATIVES OF PIPERIDINE AS INTERMEDIARIES FOR THE PREPARATION OF PAROXETINE AND PROCEDURE FOR PREPARING THEMSELVES. |
HU221921B1 (en) | 1996-07-08 | 2003-02-28 | Richter Gedeon Vegyészeti Gyár Rt. | N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them |
GB9710004D0 (en) | 1997-05-17 | 1997-07-09 | Knoll Ag | Chemical process |
IL159280A0 (en) * | 2001-06-14 | 2004-06-01 | Teva Pharma | A process for preparing paroxetine hcl which limits formation of pink colored compounds |
CN1336363A (en) * | 2001-07-25 | 2002-02-20 | 张元宾 | Synthesis of potassium acetylsulfanilate |
CA2464327A1 (en) | 2001-10-22 | 2003-05-30 | Synthon B.V. | N-formyl derivatives of paroxetine |
-
2002
- 2002-02-02 US US10/067,160 patent/US6777554B2/en not_active Expired - Fee Related
- 2002-02-04 CA CA002437392A patent/CA2437392A1/en not_active Abandoned
- 2002-02-04 WO PCT/US2002/003223 patent/WO2002062790A1/en not_active Application Discontinuation
- 2002-02-04 EP EP02702143A patent/EP1366041A4/en not_active Withdrawn
- 2002-02-04 CZ CZ20032354A patent/CZ20032354A3/en unknown
- 2002-02-04 IL IL15724302A patent/IL157243A0/en unknown
- 2002-02-04 SK SK1099-2003A patent/SK10992003A3/en unknown
- 2002-02-04 KR KR10-2003-7010266A patent/KR20040014452A/en not_active IP Right Cessation
- 2002-02-04 HU HU0303153A patent/HUP0303153A2/en unknown
-
2003
- 2003-09-01 HR HR20030690A patent/HRP20030690A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002006275A1 (en) * | 2000-07-17 | 2002-01-24 | Smithkline Beecham P.L.C. | Novel processes for the preparation of 4-phenylpiperidine derivatives |
Non-Patent Citations (1)
Title |
---|
DATABASE CAPLUS [online] (COLUMBUS, OH, USA); AGAFONOVA ET AL.: "Method of preparing alcohol of phenol difluoromethyl ethers", XP002950907, retrieved from 1995:339464 accession no. STN Database accession no. 122:132748 * |
Also Published As
Publication number | Publication date |
---|---|
EP1366041A4 (en) | 2004-12-22 |
US20020151567A1 (en) | 2002-10-17 |
SK10992003A3 (en) | 2004-03-02 |
CZ20032354A3 (en) | 2004-08-18 |
HRP20030690A2 (en) | 2005-04-30 |
HUP0303153A2 (en) | 2004-03-01 |
KR20040014452A (en) | 2004-02-14 |
EP1366041A1 (en) | 2003-12-03 |
IL157243A0 (en) | 2004-02-19 |
CA2437392A1 (en) | 2002-08-15 |
US6777554B2 (en) | 2004-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0994872A1 (en) | 4-phenylpiperidine compounds | |
EP1242083B1 (en) | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them | |
CS227007B2 (en) | Method of preparing carbazol-4-yl oxypropanolamine derivatives | |
JP2005350459A (en) | Polymorph of fexofenadine and method for producing the same | |
JPH0662519B2 (en) | Method for producing phenol ether using cyclic intermediate | |
US20040087795A1 (en) | Novel processes for the preparation of 4-phenylpiperidine derivatives | |
JP5622842B2 (en) | Method for producing alkylamine derivative | |
US6777554B2 (en) | Preparation of N-methylparoxetine and related intermediate compounds | |
JP3213324B2 (en) | Novel N-benzoylmethyl-piperidines | |
JP2011523659A (en) | Method for synthesizing levocetirizine and intermediate used therefor | |
CN100378086C (en) | Novel piperazine derivatives and their use as synthesis intermediates | |
JPH034073B2 (en) | ||
JPH0353314B2 (en) | ||
JPH0665214A (en) | Substituted (benzothiazolyl- and quinoxalinyl-methoxy)- phenylacetic acid derivative | |
JP3029876B2 (en) | Furan derivative | |
KR100808281B1 (en) | Method for the preparation of lercanidipine and acid addition salt thereof | |
JPS5822478B2 (en) | Alkylsulfonylphenoxypropanolamines | |
EP1566381B1 (en) | Process for production of 1- 2-(benzimidazol-2-yl- thio)ethyl piperazine or salts thereof | |
EP0170583B1 (en) | Ammonium salts of hexahydrodibenzodioxane derivatives, their intermediates, their preparation and their therapeutical use | |
JPH0797373A (en) | Cyclic intermediate for producing phenol ether | |
WO2001004093A2 (en) | Process for producing paroxetine derivatives by mitsunobu reaction | |
JPS6128660B2 (en) | ||
KR950002832B1 (en) | Process for the preparation of phenol ethers | |
JPH0827154A (en) | Azachroman derivative and its use | |
WO2007034270A2 (en) | Improved process for the preparation of (-) trans-n-methyl paroxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2437392 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037010266 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 157243 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20030690A Country of ref document: HR Ref document number: PV2003-2354 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10992003 Country of ref document: SK Ref document number: 2002702143 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002702143 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037010266 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-2354 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002702143 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020037010266 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV2003-2354 Country of ref document: CZ |